Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does bronchial hyperresponsiveness in asthma matter?

Graeme P Currie1, Catherine M Jackson, Brian J Lipworth

  • 1Chest Clinic C, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK.

The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|July 21, 2004
PubMed
Summary

Bronchial hyperresponsiveness, a key asthma feature, causes airway narrowing. Asthma medications can reduce this hyperresponsiveness, aiding in better patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma.

Clinical and translational allergy·2026
Same author

Impact of dupilumab on Sino-Nasal Outcome Test-22 (SNOT-22) domains: Focus on the ear.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Impact of dupilumab on united airways disease.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Bucher indirect treatment comparison of phase 3 trials with dupilumab and tezepelumab in chronic rhinosinusitis with nasal polyps.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD.

The journal of allergy and clinical immunology. In practice·2026

Area of Science:

  • Pulmonology
  • Clinical Medicine
  • Pharmacology

Background:

  • Bronchial hyperresponsiveness is central to asthma's inflammatory process, leading to airway narrowing and symptoms like wheezing and cough.
  • It is triggered by exposure to bronchoconstrictor stimuli, significantly impacting patient quality of life.

Purpose of the Study:

  • To review the impact of asthma pharmacotherapy on bronchial hyperresponsiveness.
  • To assess how measuring bronchial hyperresponsiveness aids in evaluating asthma treatment efficacy.
  • To explore the role of bronchial hyperresponsiveness in optimal asthma management strategies.

Main Methods:

  • Discussion of existing literature on inhaled and oral asthma treatments.
  • Analysis of bronchial challenge tests used to quantify bronchial hyperresponsiveness.

Related Experiment Videos

  • Review of how pharmacotherapy affects responses to direct and indirect stimuli.

    • Main Results:

    • Asthma pharmacotherapy, including inhaled and oral treatments, can attenuate bronchial hyperresponsiveness.
    • The degree of attenuation in bronchial hyperresponsiveness serves as a crucial measure of treatment efficacy.
    • Bronchial hyperresponsiveness monitoring complements conventional asthma control metrics.

    Conclusions:

    • Evaluating bronchial hyperresponsiveness is vital for assessing asthma pharmacotherapy effectiveness.
    • Integrating bronchial hyperresponsiveness assessment into patient management can lead to more optimal asthma control.
    • This approach supports personalized treatment strategies for asthma patients.